Related Experiment Video
Updated: Jul 7, 2026
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
INDIVIDUAL ARTICLE: A Practical Algorithm for the Prevention and Treatment of Cutaneous Side Effects of Hormonal
Introduction:
Hormonal therapies, typically used in the treatment of breast and prostate cancer patients, have been associated with numerous skin toxicities that can impact quality of life and interfere with treatment adherence. Appropriate management is necessary to improve the quality of life for cancer patients and survivors who experience hormonal therapy-related dermatologic toxicities. Objectives: To develop a practical, physician-developed algorithm for the management of hormonal therapy-related cutaneous adverse events using prescription treatment and non-prescription skincare.
Methods:
The Nordic European Cutaneous Oncodermatology Management (NECOM) 6 advisory board integrated evidence from a structured literature search with the panel's expertise and clinical insights to create a practical algorithm for preventing and treating flushing/hot flashes, pruritus/urticaria, rosacea, alopecia, hirsutism, and hyperhidrosis associated with hormonal therapy. Results: An algorithm that aims to improve patient comfort during and after treatment, reduce the incidence of hormonal therapy-related cutaneous adverse events, and promote healing of affected skin areas by using prescription medication and skincare. Suggested management recommendations supplement the algorithm.
Conclusions:
Preventing and treating common dermatologic toxicities associated with hormonal cancer therapies is an essential component of care to improve patient quality of life, adherence to cancer treatment, and treatment outcomes. The NECOM 6 algorithm provides management strategies for all HCPs who treat oncology patients to prevent and treat common cutaneous adverse events associated with hormonal cancer therapies. J Drugs Dermatol. 2025;24:5(Suppl 1):s3-10. .
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Survival Analysis
Acne Infection

